Your search for ‘Smart & Biggar’ returned 2,497 results

The "Office québécois de la langue française" (the Office) announced on June 1, 2012, that starting this summer, it would conduct investigations on its own initiative

As previously reported, Amgen sought leave to appeal a decision of the Federal Court of Appeal (2020 FCA 188) affirming Justice Southcott's decision that the relevant claims of its filgrastim (NEUPOGEN)

In many countries, during trade-mark prosecution, a letter of consent can be filed to overcome a citation of another mark.

Canada’s laws provide a one-year grace period for public disclosures by the applicant (or by a person who obtained knowledge of an invention from the applicant) calculated from the Canadian filing date.

The firm was chosen as the 2016 Canadian Specialty IP Firm of the Year and as the Canadian Trademark Contentious Firm of the Year.

On April 23, 2018, the Competition Bureau announced an agreement whereby Metro will sell properties/leases and take steps to terminate agreements relating to pharmacies in certain Quebec markets.

Crowdfunding has quickly become a popular method of raising capital on the Internet, and can lift small and medium-sized companies off the ground.

On September 1, 2022, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced the launch of its Post-Market Drug Evaluation Program.

CADTH proposals to enhance drug review processes.

Canada's Drug Agency has released new guidance on using artificial intelligence methods to generate real-world evidence for health technology assessments, establishing governance considerations and appraisal principles that emphasize transparency, human oversight, and validation. The agency also launched initiatives supporting precision medicine decision-making, including testing procedure assessments and a pan-Canadian framework for biomarker evaluation in cancer care.

The strategy, titled, "A Prescription for Action: A Pan-Canadian Strategy for Advancing the Appropriate Use of Prescription Medications" provides a 5-year plan to foster a unified national approach that promotes safer, more effective medication use and strengthens health system sustainability.

The Competition Bureau's investigation concluded that NuvoCare's weight loss claims were not supported by adequate and proper testing.

The United States Food and Drug Administration (FDA) released Draft Guidance on February 9, 2012 for obtaining approval of subsequent-entry versions of biologic drugs (also known as biosimilars).

As previously reported, a proposed class action proceeding against over 50 generic drug manufacturers was commenced in 2020.

On September 30, 2020, the Federal Court dismissed an application by Catalyst Pharmaceuticals Inc and KYE Pharmaceuticals Inc (collectively, the applicants) for an interlocutory injunction to stay the decision of the Minister of Health ...

Health Canada intends to pre-publish the proposed regulatory amendments in 2019.

On November 20, 2024, Health Canada posted Drug shortages in Canada: Fiscal year 2023 to 2024 in review. The review includes an overview of drug shortages...

On February 7, 2018, Health Canada published an update to the guidance document Classification of Products at the (Medical) Device-Drug Interface.